Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Biocapital exchanges : Amex save search
CEL-SCI Announces Closing of $7.75 Million Public Offering of Common Stock
Published: 2024-02-13 (Crawled : 19:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 1.27%
H: 0.0%
C: -4.18%
million offering
CEL-SCI Announces Pricing of $7.75 Million Public Offering of Common Stock
Published: 2024-02-09 (Crawled : 14:30) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: -17.54%
H: 9.97%
C: 4.68%
million offering
European Medicines Agency Grants CEL-SCI a Waiver of Strict Pediatric Requirements, Clearing the Path Towards Marketing Authorization for Multikine®
Published: 2024-01-31 (Crawled : 21:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 1.75%
H: 6.21%
C: -1.03%
multikine authorization grants
Senseonics Holdings, Inc. to Participate in the Stifel 2023 Healthcare Conference
Published: 2023-11-09 (Crawled : 15:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 0.0%
H: 0.27%
C: -1.1%
conference
CEL-SCI Corporation Reports Third Quarter Fiscal 2023 Financial Results
Published: 2023-08-11 (Crawled : 21:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: -0.7%
H: 0.71%
C: -12.06%
corporation financial results
New Clinical Data Demonstrating the Safety and Accuracy of Eversense through 365 Days Presented at the American Diabetes Association 83rd Scientific Sessions
Published: 2023-06-26 (Crawled : 12:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 5.28%
H: 1.16%
C: -16.22%
association eversense sessions diabetes
Senseonics Announces UnitedHealthcare Coverage of Eversense® E3 CGM for Adults with Diabetes
Published: 2023-06-02 (Crawled : 12:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 15.32%
H: 2.08%
C: 0.72%
eversense diabetes
CEL-SCI Announces $1.35 Million Underwritten Confidentially Marketed Public Offering of Common Stock
Published: 2023-04-28 (Crawled : 08:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: -11.74%
H: 13.3%
C: 12.23%
offering
CEL-SCI to Pursue Canada’s Conditional Approval Pathway for Multikine in the Treatment of Head & Neck Cancer
Published: 2023-04-19 (Crawled : 22:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 1.63%
H: 17.6%
C: 13.2%
multikine approval cancer treatment
Senseonics Announces the First Pediatric Study Participant Insertions in the ENHANCE Clinical Trial
Published: 2023-04-18 (Crawled : 00:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 1.46%
H: 7.21%
C: 6.39%
trial study
CEL-SCI Corporation Reports First Quarter Fiscal 2023 Financial Results
Published: 2023-02-15 (Crawled : 15:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: -1.13%
H: 4.15%
C: 0.76%
corporation financial results
CEL-SCI’S Multikine Reduced 5-year Death Rate From 54% to 22% in Phase 3 Study Patients Who Were Early Tumor Responders Prior to Any Standard of Care Treatment
Published: 2022-10-17 (Crawled : 13:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 3.8%
H: 2.97%
C: 0.61%
treatment care multikine study
CEL-SCI’S Phase 3 Data Presented at ESMO 2022: Neoadjuvant Multikine Achieved Groundbreaking Tumor Response & Extended Overall Survival in Locally Advanced Head and Neck Cancer
Published: 2022-09-12 (Crawled : 14:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 2.38%
H: 1.63%
C: -2.79%
multikine response cancer
CEL-SCI Corporation Announces Phase 3 Multikine® Head and Neck Cancer Results Posted on Clinicaltrials.gov
Published: 2022-08-19 (Crawled : 13:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: 0.71%
H: 12.94%
C: 3.06%
multikine corporation results cancer
Senseonics Announces a Positive Coverage Decision for Eversense® E3 CGM from Anthem
Published: 2022-08-03 (Crawled : 12:20) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 6.3%
H: 24.44%
C: 23.7%
eversense positive
Senseonics Holdings, Inc. Schedules Second Quarter 2022 Earnings Release and Conference Call for August 9, 2022, at 4:30 p.m. Eastern Time
Published: 2022-07-26 (Crawled : 01:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: -1.59%
H: 0.81%
C: -4.84%
conference
Senseonics Announces the First Patient Implant of the Eversense E3 CGM System in the U.S.
Published: 2022-04-06 (Crawled : 00:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: -1.64%
H: 2.22%
C: 1.11%
system implant eversense
Eversense NOW Remote Monitoring App for Android Users Receives CE Mark in Europe
Published: 2021-12-21 (Crawled : 15:30) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 3.07%
H: 6.32%
C: 3.35%
europe ce mark
CEL-SCI Corporation Reports Third Quarter Fiscal 2021 Financial Results
Published: 2021-08-16 (Crawled : 14:00) - biospace.com/
CVM | $1.59 -2.45% -3.15% 170K
|
Health Technology
|
| O: -1.44%
H: 5.96%
C: 1.8%
financial results results cel
Senseonics Holdings, Inc. Reports Second Quarter 2021 Financial Results
Published: 2021-08-09 (Crawled : 21:00) - biospace.com/
SENS | $0.4371 -9.13% 0.64% 6M
|
Electronic Technology
|
| O: 3.42%
H: 0.9%
C: -2.4%
financial results results
Gainers vs Losers
| 48% | 52% |
Top 10 Gainers
KAVL | $6.3 135.96% 57.45% 44M
|
Wholesale Trade
PXMD | $0.7375 79.09% 44.16% 4.5M
|
Health Technology
DYNT | $0.3704 -5.27% 43.09% 1.6M
|
Health Technology
LGVN P 3 d | $2.93 73.37% 42.52% 56M
|
HUBC | $1.95 50.0% 32.99% 73M
|
n/a
SPCB | $0.4044 46.52% 31.75% 130M
|
Electronic Technology
ONVO | $1.34 32.66% 24.62% 54M
|
Health Technology
OMQS | $0.6869 32.1% 24.3% 3.6M
|
Professional, Scientific, and T...
SNPO | $10.555 29.67% 22.88% 4M
|
EEIQ | $1.16 27.46% 20.86% 6.9K
|
Educational Services
Your saved searches
Save your searches and get alerts when important news are released.